PACS Group (NYSE:PACS) Stock: Insider Jason Hulse Murray Sells 31,358 Shares

PACS Group, Inc. (NYSE:PACS) CEO Jason Murray sold 31,358 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $46.02, for a total value of $1,443,095.16. Following the completion of the transaction, the chief executive officer owned 54,148,039 shares of the company’s stock, valued at $2,491,892,754.78. This trade represents a 0.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jason Hulse Murray also recently made the following trade(s):

• On Wednesday, November 4th, Jason Murray sold 167,434 shares of PACS Group stock. The stock was sold at an average price of $50.24, for a total value of $8,411,884.16.
• On Tuesday, November 3rd, Jason Murray sold 26,504 shares of PACS Group stock. The shares were sold at an average price of $46.50, for a total value of $1,232,436.00.
• On Thursday, October 29th, Jason Murray sold 1,904 shares of PACS Group stock. The shares were sold at an average price of $50.05, for a total value of $95,295.20.
• On Wednesday, October 28th, Jason Murray sold 6,899 shares of PACS Group stock. The shares were sold at an average price of $50.10, for a total value of $345,639.90.
• On Friday, October 23rd, Jason Murray sold 68,917 shares of PACS Group stock. The stock was sold at an average price of $48.60, for a total value of $3,349,366.20.
• On Thursday, October 22nd, Jason Murray sold 13,696 shares of PACS Group stock. The stock was sold at an average price of $47.55, for a total value of $651,244.80.
• On Wednesday, October 21st, Jason Murray sold 6,610 shares of PACS Group stock. The stock was sold at an average price of $47.62, for a total value of $314,768.20.
• On Tuesday, October 20th, Jason Murray sold 37,477 shares of PACS Group stock. The shares were sold at an average price of $47.65, for a total value of $1,785,779.05.
• On Monday, October 19th, Jason Murray sold 1,620 shares of PACS Group stock. The shares were sold at an average price of $47.57, for a total value of $77,063.40.
• On Friday, October 16th, Jason Murray sold 8,462 shares of PACS Group stock. The stock was sold at an average price of $47.61, for a total transaction of $402,875.82.

PACS Group Price Performance

Shares of NYSE:PACS opened at $50.03 on Friday. PACS Group, Inc. has a twelve month low of $10.31 and a twelve month high of $51.68. The company has a current ratio of 0.80, a quick ratio of 0.91 and a debt-to-equity ratio of 0.22. The company has a market cap of $7.94 billion, a PE ratio of 22.95, a price-to-earnings-growth ratio of 1.57 and a beta of -0.14. The company’s 50 day moving average is $44.53 and its 200 day moving average is $39.96.

PACS Group (NYSE:PACS) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.58 by $0.05. The business had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.46 billion. PACS Group had a net margin of 4.87% and a return on equity of 31.98%. On average, sell-side analysts forecast that PACS Group, Inc. will post 2.13 EPS for the current year.

PACS Group News Roundup

Here are the key news stories impacting PACS Group this week:

• Positive Sentiment: Third-quarter EPS of $0.63 topped estimates of $0.58, while revenue of $1.50 billion exceeded the $1.46 billion consensus. Adjusted EBITDA reportedly rose 33.6%, reinforcing evidence of operating growth. PACS Group, Inc. Reports Third Quarter 2026 Results PACS Group Q3 2026: EBITDA Surges 33.6%
• Positive Sentiment: PACS raised its 2026 revenue outlook to $5.95 billion–$6.05 billion and adjusted EBITDA guidance to $685 million–$695 million. The company also highlighted acquisitions in Florida and Texas and facility occupancy around 90%, supporting its expansion story. PACS raises 2026 outlook PACS acquisitions and Q3 results
• Positive Sentiment: Truist reaffirmed its Buy rating and raised its target to $65 from $62; Stephens raised its target to $64 from $60 and assigned an Overweight rating. Higher targets signal continued analyst confidence in potential upside. Truist analyst ratings Stephens analyst ratings
• Negative Sentiment: The CEO, a director, and the chief accounting officer reported share sales. These could weigh slightly on sentiment, but the trades were made under pre-arranged Rule 10b5-1 plans, and the CEO and director retained large holdings. PACS insider transactions

Hedge Funds Weigh In On PACS Group

Several large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its holdings in PACS Group by 370.2% in the first quarter. Dimensional Fund Advisors LP now owns 780,159 shares of the company’s stock valued at $25,051,000 after buying an additional 614,250 shares in the last quarter. Sei Investments Co. raised its position in shares of PACS Group by 7.4% in the first quarter. Sei Investments Co. now owns 370,501 shares of the company’s stock worth $11,900,000 after acquiring an additional 25,462 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of PACS Group by 44.6% in the first quarter. Arrowstreet Capital Limited Partnership now owns 288,718 shares of the company’s stock worth $9,274,000 after acquiring an additional 89,067 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of PACS Group in the second quarter worth about $8,196,000. Finally, Corient Private Wealth LP boosted its stake in shares of PACS Group by 1.8% during the 2nd quarter. Corient Private Wealth LP now owns 152,846 shares of the company’s stock worth $6,517,000 after acquiring an additional 2,680 shares in the last quarter.

Wall Street Analyst Weigh In

PACS has been the topic of several recent research reports. Truist Financial reaffirmed a “buy” rating and issued a $65.00 price target (up from $62.00) on shares of PACS Group in a report on Thursday. Oppenheimer boosted their price objective on PACS Group from $48.00 to $57.00 and gave the company an “outperform” rating in a report on Monday, August 10th. Stephens boosted their price objective on PACS Group from $60.00 to $64.00 and gave the company an “overweight” rating in a report on Thursday. JPMorgan Chase & Co. upped their target price on PACS Group from $47.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, September 4th. Finally, Wall Street Zen lowered PACS Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, PACS Group currently has an average rating of “Moderate Buy” and a consensus target price of $61.33.

About PACS Group

PACS Group, Inc is a U.S.-based healthcare services company that owns and operates post-acute care facilities. Its platform focuses primarily on skilled nursing and transitional care, serving patients who require rehabilitation, recovery support, long-term care, and other services following hospitalization or acute medical treatment.

The company’s operations also include assisted living, independent living, and behavioral health services in select locations. Through its facilities and related healthcare capabilities, PACS Group provides services such as nursing care, physical and occupational therapy, speech therapy, medical treatment, and support for patients with complex or extended care needs.

Founded in 2013 and headquartered in Farmington, Utah, PACS Group serves communities across multiple U.S.